Get the Stockscreener App
1,107.64
0.59%
5.56
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,107.64, with a volume of 1.99M.
It is up +0.59% in the last 24 hours and up +4.09% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,102.08
Open:
$1117
24h Volume:
1.99M
Relative Volume:
0.63
Market Cap:
$987.97B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
39.87
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-1.24%
1M Performance:
+4.09%
6M Performance:
+3.45%
1Y Performance:
+43.85%
1-Day Range:
$1,079.22
$1,122.02
1-Week Range:
$1,079.22
$1,122.33
52-Week Range:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,107.91 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
238.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
233.44 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.14 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.95 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) Plans European Launch of Weight-Loss Pill by 202 - GuruFocus
Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support - GlobeNewswire Inc.
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle - Benzinga
Eli Lilly and Bayer hit out at Germany’s spending on new medicines - Financial Times
Eli Lilly Chose One 79-Year-Old for Retatrutide While Millions Rely on Gray Market - Tech Times
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe - Reuters
Eli Lilly plans European weight-loss pill launch by early 2027 - Investing.com
Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient - The New Republic
Illumina adds Eli Lilly executive to board of directors - Investing.com
Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets - The Business Journals
Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program - statnews.com
Sangamo files for Chapter 11, signs asset sale deals with Lilly - Investing.com
Lilly allows one-time access to next-gen obesity drug (update) - Seeking Alpha
Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets - Seeking Alpha
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? - statnews.com
Lilly and BioArctic sign deal to develop neurodegenerative therapy - Pharmaceutical Technology
Eli Lilly deploys weight-loss cash on ‘App Store’ for scientists - Financial Times
Lilly declares third-quarter 2026 dividend - investor.lilly.com
Eli Lilly and Co To Go Ex-Dividend On August 14th, 2026 With 1.73 USD Dividend Per Share - 富途牛牛
Watch How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle - Bloomberg
Eli Lilly (LLY) Receives Approval for Centessa Acquisition Deal - GuruFocus
Lilly’s $7.8 billion Centessa acquisition gets court approval - Investing.com
Lilly’s $7.8 billion Centessa acquisition gets court approval By Investing.com - Investing.com Canada
Acquisition Of Centessa By Lilly Approved By The High Court Of Justice Of England And Wales CNTA - Moomoo
Can Eli Lilly (NYSE:LLY) GLP-1 Pill Reshape The Conversation? - Kalkine Media
BioArctic, Lilly Ink Research Alliance - Contract Pharma
Is Eli Lilly (NYSE:LLY) Opening A New Growth Chapter? - Kalkine Media
How Eli Lilly Got Huge By Making Us Thin - Bloomberg
Eli Lilly declares $1.73 quarterly dividend By Investing.com - Investing.com Canada
Is Eli Lilly and Company (LLY) among the Best Longevity and Anti-Aging Stocks to Buy? - Insider Monkey
Cantor Fitzgerald reiterates Eli Lilly stock Overweight rating at $1,230 - Investing.com
Bioarctic and Lilly partner in neurodegeneration - BioWorld News
Cantor Fitzgerald reiterates Eli Lilly stock Overweight rating at $1,230 By Investing.com - Investing.com Canada
Lilly bets up to $800M for BioArctic’s brain delivery tech - BioSpace
Eli Lilly & Co. (NYSE:LLY): A High-Growth Champion Aligned with Navellier's Proven Strategy - ChartMill
Eli Lilly (LLY) Partners with BioArctic for Neurodegeneration Tr - GuruFocus
Eli Lilly and Company (LLY) Stock Analysis: Navigating a 10.94% Upside Potential and Robust Revenue Growth - DirectorsTalk Interviews
BioArctic, Eli Lilly ink deal to combine drug-delivery tech with Lilly compound - Investing.com Canada
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology - Yahoo Finance Singapore
BioArctic and Lilly Sign Research and Collaboration Agreement Combining Lilly Compound With BioArctic's BrainTransporter Technology - Moomoo
Eli Lilly StockWeekly outlook with earnings and obesity focus - AD HOC NEWS
Watch How Eli Lilly Became a $1 Trillion Company - Bloomberg
Eli Lilly Stock (LLY) Opinions on Pipeline Expansions and Regulatory Risks - Quiver Quantitative
3 Reasons to Buy Eli Lilly Stock - AOL.com
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. - The Motley Fool
AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths - NAI500
New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway - PR Newswire
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentals - ChartMill
Charles River collaborates with Lilly TuneLab platform - Yahoo Finance
Eli Lilly cuts 340B discounts for hospitals resisting its claims data submission policy - Fierce Healthcare
Why Are Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) Driving S&P 500 Healthcare Focus? - Kalkine Media
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):